U.S. TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET ANALYSIS

U.S. Transthyretin Amyloidosis Treatment Market, By Type (Hereditary Transthyretin Amyloidosis (hATTR-CM) and Wild Type Amyloidosis), By Drug Type (Tafamidis, Diflunisal, Inotersen, Patisiran, Tolcapone, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)

Published In : Nov 2024
Code : CMI1919
Pages :116
Formats :
Excel and PDF
Industry : Pharmaceutical

Key Takeaways from Analyst

The increasing prevalence rate of the disease is expected to be a major growth driver as it raises awareness and demand for effective treatment options. In addition, recent drug approvals for hereditary and wild-type ATTR amyloidosis provide patients with important new therapies.

In addition, recent drug approvals for hereditary and wild-type ATTR amyloidosis provide patients with important new therapies. This has expanded treatment choices for physicians and broadened the addressable patient pool.

High drug prices remain a restraint for market expansion as not all patients have adequate insurance coverage for the costly medications. This could limit their adoption. Nonetheless, pharmaceutical companies are making efforts to offer patient support programs to improve access.